Paul Peter Tak
Chief Executive Officer at Candel Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Candel Therapeutics Inc., 3 years.
Candel Therapeutics Inc.
Director · Chief Executive Officer
Chief executive roles
Candel Therapeutics Inc.
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 19, 2025 | Candel Therapeutics Inc. | Open-market sale | −400 | $9.00 | $3,600 |
| Mar 18, 2025 | Candel Therapeutics Inc. | Open-market sale | −25,772 | $8.77 | $226,020 |
| Nov 29, 2024 | Candel Therapeutics Inc. | Open-market sale | −48,847 | $4.56 | $222,742 |
| Nov 21, 2024 | Candel Therapeutics Inc. | Option exercise | +12,900 | $1.55 | $19,995 |
| Jul 17, 2024 | Candel Therapeutics Inc. | Open-market sale | −22,528 | $6.47 | $145,756 |
| Jul 11, 2024 | Candel Therapeutics Inc. | Open-market sale | −20,293 | $5.97 | $121,149 |
| Nov 28, 2023 | Candel Therapeutics Inc. | Shares withheld for tax | −43,443 | $0.90 | $39,099 |
| Nov 26, 2023 | Candel Therapeutics Inc. | Grant or award | +180,108 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.